Complement-driven anemia: More than just paroxysmal nocturnal hemoglobinuria

Keyphrases

• Anemia 100%
• Paroxysmal Nocturnal Hemoglobinuria 100%
• Atypical Hemolytic Uremic Syndrome (aHUS) 66%
• Alternative Complement Pathway 66%
• Monoclonal Antibody 33%
• Inflammation 33%
• Stem Cells 33%
• Germ Cells 33%
• Heterozygous mutation 33%
• Penetrance 33%
• U.S. Food 33%
• Clinically Significant Disease 33%
• Erythrocytes 33%
• Hemolytic Anemia 33%
• Complement Activation 33%
• Complement Cascade 33%
• Endothelial Damage 33%
• Eculizumab 33%
• Intravascular Hemolysis 33%
• Complement Inhibitors 33%
• Related Conditions 33%
• CD59 33%
• CD55 33%
• Elevated Liver Function Tests 33%
• Hematopoietic Disorders 33%
• Thrombotic Microangiopathy 33%
• Blood Cells 33%
• Pre-clinical and Clinical Trials 33%
• Complement Regulators 33%
• Platelet Consumption 33%
• Complement Components 33%
• C5 Convertase 33%
• Microthrombi 33%
• Schistocytes 33%
• Low Platelets Syndrome 33%

Medicine and Dentistry

• Anemia 100%
• Paroxysmal Nocturnal Hemoglobinuria 100%
• Disease 66%
• Platelet 66%
• Atypical Hemolytic Uremic Syndrome 66%
• Monoclonal Antibody 33%
• Stem Cell 33%
• Clinical Trial 33%
• Transplantation 33%
• Liver Function Test 33%
• Hemolytic Anemia 33%
• Microangiopathy 33%
• Erythrocyte 33%
• Regulator Protein 33%
• Decay Accelerating Factor 33%
• Intravascular Hemolysis 33%
• Penetrance 33%
• Complement Activation 33%
• Eculizumab 33%
• Complement Inhibitor 33%
• Blood Cell 33%
• Microthrombus 33%
• Schistocyte 33%
• Complement Regulator 33%

Biochemistry, Genetics and Molecular Biology

• Schistocyte 50%